Published in J Med Chem on October 27, 2007
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem (2008) 1.18
Lipophilic pyridinium bisphosphonates: potent gammadelta T cell stimulators. Angew Chem Int Ed Engl (2010) 1.03
Polyoxometalates functionalized by bisphosphonate ligands: synthesis, structural, magnetic, and spectroscopic characterizations and activity on tumor cell lines. Inorg Chem (2012) 0.81
Ab initio DFT study of bisphosphonate derivatives as a drug for inhibition of cancer: NMR and NQR parameters. J Mol Model (2011) 0.77
In Vitro and In Vivo Investigation of the Inhibition of Trypanosoma brucei Cell Growth by Lipophilic Bisphosphonates. Antimicrob Agents Chemother (2015) 0.76
Anticancer Activity of Polyoxometalate-Bisphosphonate Complexes: Synthesis, Characterization, In Vitro and In Vivo Results. Inorg Chem (2017) 0.75
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet (2011) 4.02
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs. J Med Chem (2002) 3.82
A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science (2008) 2.96
Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem (2004) 2.41
Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A (2007) 2.00
Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem (2006) 1.98
An NMR investigation of CO tolerance in a Pt/Ru fuel cell catalyst. J Am Chem Soc (2002) 1.94
Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol (2012) 1.87
Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. J Am Chem Soc (2009) 1.75
Antibacterial drug leads targeting isoprenoid biosynthesis. Proc Natl Acad Sci U S A (2012) 1.69
Nitric-oxide-mediated zinc release contributes to hypoxic regulation of pulmonary vascular tone. Circ Res (2008) 1.67
Structure of (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate reductase, the terminal enzyme of the non-mevalonate pathway. J Am Chem Soc (2008) 1.57
Bioorganometallic mechanism of action, and inhibition, of IspH. Proc Natl Acad Sci U S A (2010) 1.54
Solid-state NMR, crystallographic, and computational investigation of bisphosphonates and farnesyl diphosphate synthase-bisphosphonate complexes. J Am Chem Soc (2006) 1.48
Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design. Proteins (2006) 1.47
Diterpene cyclases and the nature of the isoprene fold. Proteins (2010) 1.41
3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. J Med Chem (2003) 1.35
Farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei. In vitro RNA interference and in vivo inhibition studies. J Biol Chem (2003) 1.31
Carbon-13 NMR shielding in the twenty common amino acids: comparisons with experimental results in proteins. J Am Chem Soc (2002) 1.29
Organometallic mechanism of action and inhibition of the 4Fe-4S isoprenoid biosynthesis protein GcpE (IspG). Proc Natl Acad Sci U S A (2010) 1.28
Isomer separation, conformation control of flexible cyclohexanedicarboxylate ligand in cadmium complexes. Chem Commun (Camb) (2004) 1.25
Multitarget drug discovery for tuberculosis and other infectious diseases. J Med Chem (2014) 1.24
Neuroprotective effects of ginsenoside Rd against oxygen-glucose deprivation in cultured hippocampal neurons. Neurosci Res (2009) 1.23
Enthalpy versus entropy-driven binding of bisphosphonates to farnesyl diphosphate synthase. J Am Chem Soc (2006) 1.22
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J Med Chem (2002) 1.22
(57)Fe Mössbauer isomer shifts of heme protein model systems: electronic structure calculations. J Am Chem Soc (2002) 1.21
Bisphosphonate inhibition of a Plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data. J Med Chem (2008) 1.21
A density functional theory investigation of Fe-N-O bonding in heme proteins and model systems. J Am Chem Soc (2003) 1.21
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. J Med Chem (2004) 1.21
Inhibition of the Fe(4)S(4)-cluster-containing protein IspH (LytB): electron paramagnetic resonance, metallacycles, and mechanisms. J Am Chem Soc (2010) 1.21
Thermodynamics of bisphosphonates binding to human bone: a two-site model. J Am Chem Soc (2009) 1.21
Photoaffinity antigens for human gammadelta T cells. J Immunol (2008) 1.19
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem (2008) 1.18
A novel custom resequencing array for dilated cardiomyopathy. Genet Med (2010) 1.18
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. J Med Chem (2004) 1.16
The farnesyl-diphosphate/geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates. J Biol Chem (2007) 1.16
Ultrahigh resolution protein structures using NMR chemical shift tensors. Proc Natl Acad Sci U S A (2011) 1.15
In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob Agents Chemother (2002) 1.14
Cytochrome P450: an investigation of the Mössbauer spectra of a reaction intermediate and an Fe(IV)[double bond]O model system. J Am Chem Soc (2004) 1.13
Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design. Chem Biol Drug Des (2011) 1.13
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations. J Med Chem (2005) 1.13
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. J Med Chem (2005) 1.12
Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem (2002) 1.11
Mechanism of action and inhibition of dehydrosqualene synthase. Proc Natl Acad Sci U S A (2010) 1.11
A solid state 13C NMR, crystallographic, and quantum chemical investigation of chemical shifts and hydrogen bonding in histidine dipeptides. J Am Chem Soc (2005) 1.10
The H(+)-pyrophosphatase of Rhodospirillum rubrum is predominantly located in polyphosphate-rich acidocalcisomes. J Biol Chem (2004) 1.10
Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi. Int J Antimicrob Agents (2004) 1.10
Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. J Infect Dis (2002) 1.10
Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity. Proc Natl Acad Sci U S A (2012) 1.09
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin. J Med Chem (2006) 1.09
NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model. J Am Chem Soc (2008) 1.09
On the Mössbauer spectra of isopenicillin N synthase and a model (FeNO)7 (S = 3/2) system. J Am Chem Soc (2004) 1.08
Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth. Antimicrob Agents Chemother (2010) 1.07
A novel bilayer cobalt(II)-organic framework with nanoscale channels accommodating large organic molecules. Inorg Chem (2003) 1.05
Lipophilic pyridinium bisphosphonates: potent gammadelta T cell stimulators. Angew Chem Int Ed Engl (2010) 1.03
Mössbauer quadrupole splittings and electronic structure in heme proteins and model systems: a density functional theory investigation. J Am Chem Soc (2002) 1.03
Phosphoketolase pathway dominates in Lactobacillus reuteri ATCC 55730 containing dual pathways for glycolysis. J Bacteriol (2007) 1.02
Are free radicals involved in IspH catalysis? An EPR and crystallographic investigation. J Am Chem Soc (2012) 1.02
Farnesyl diphosphate synthase inhibitors from in silico screening. Chem Biol Drug Des (2013) 1.02
Protein structure refinement using 13C alpha chemical shift tensors. J Am Chem Soc (2009) 1.01
Molecular manipulation targeting regulation of dopaminergic differentiation and proliferation of neural stem cells or pluripotent stem cells. CNS Neurol Disord Drug Targets (2011) 1.00
Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int J Antimicrob Agents (2004) 1.00
Fluoro-Jade C can specifically stain the degenerative neurons in the substantia nigra of the 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine-treated C57BL/6 mice. Brain Res (2007) 0.99
Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem (2009) 0.99
Magic-angle spinning (31)P NMR spectroscopy of condensed phosphates in parasitic protozoa: visualizing the invisible. FEBS Lett (2002) 0.98
Pyridine inhibitor binding to the 4Fe-4S protein A. aeolicus IspH (LytB): a HYSCORE Investigation. J Am Chem Soc (2011) 0.98
Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism. J Immunol (2011) 0.97
Reversible color changes of metal(II)-N(1),N(3)-di(pyridin-4-yl)isophthalamide complexes via desolvation and solvation. Dalton Trans (2010) 0.97
Crystallographic structures of two bisphosphonate:1-deoxyxylulose-5-phosphate reductoisomerase complexes. J Am Chem Soc (2004) 0.97
Identifying unexpected therapeutic targets via chemical-protein interactome. PLoS One (2010) 0.97
Interpenetrated metal-organic frameworks of self-catenated four-connected mok nets. Chem Commun (Camb) (2011) 0.96